Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome

BMC Infectious Diseases

Elisabeth Paramythiotou⁶  Apostolos Armaganidis⁶  Charalambos Gogos⁴  Ioannis Pneumatikos⁷  Evangelos J Giamarellos-Bourboulis⁹  Dimitrios Sinapidis³  Antonios Papadopoulos⁹  Konstantinos Makaritsis⁵  Christos Nathanail²  Ioannis Perdios¹  Glykeria Vlachogiannis⁸  Nikolaos Antonakos⁹  Theodoros Retsas³  Marina Koupetori^1,10 

[1] Intensive Care Unit, Artas General Hospital, Artas, Greece;Department of Internal Medicine, General Hospital of the University of Thessaly, Larissa, Greece;Department of Therapeutics, University of Athens, Medical School, Athens, Greece;Department of Internal Medicine, University of Patras, Rion, Greece;1st Department of Internal Medicine, G.Gennimatas General Hospital, Athens, Greece;2nd Department of Critical Care Medicine, University of Athens, Medical School, Athens, Greece;Intensive Care Unit, Democriteion University Hospital, Alexandroupolis, Greece;Intensive Care Unit, Aghios Dimitrios General Hospital, Thessaloniki, Greece;4th Department of Internal Medicine, University of Athens, Medical School, 1 Rimini Street, 12462 Athens, Greece;1st Department of Internal Medicine, Thriassio General Hospital, Elefsis, Greece

关键词: Resistance;    De-escalation;    Sepsis;    Bloodstream infections;   

Others  :  1127765
DOI  :  10.1186/1471-2334-14-272

 received in 2014-02-28, accepted in 2014-05-12,  发布年份 2014

【 摘 要 】

Background

Choice of empirically prescribed antimicrobials for sepsis management depends on epidemiological factors. The epidemiology of sepsis in Greece was studied in two large-periods.

Methods

Sepsis due to bloodstream infections (BSI) from July 2006 until March 2013 was recorded in a multicenter study in 46 departments. Patients were divided into sepsis admitted in the emergencies and hospitalized in the general ward (GW) and sepsis developing after admission in the Intensive Care Unit (ICU). The primary endpoints were the changes of epidemiology and the factors related with BSIs by multidrug-resistant (MDR) pathogens; the secondary endpoint was the impact of de-escalation on antimicrobial therapy.

Results

754 patients were studied; 378 from 2006–2009 and 376 from 2010–2013. Major differences were recorded between periods in the GW. They involved increase of: sepsis severity; the incidence of underlying diseases; the incidence of polymicrobial infections; the emergence of Klebsiella pneumoniae as a pathogen; and mortality. Factors independently related with BSI by MDR pathogens were chronic hemofiltration, intake of antibiotics the last three months and residence into long-term care facilities. De-escalation in BSIs by fully susceptible Gram-negatives did not affect final outcome. Similar epidemiological differences were not found in the ICU; MDR Gram-negatives predominated in both periods.

Conclusions

The epidemiology of sepsis in Greece differs in the GW and in the ICU. De-escalation in the GW is a safe strategy.

【 授权许可】

   
2014 Koupetori et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Bearman GM, Wenzel RP: Bacteremias: a leading cause of death. Arch Med Res 2005, 36:646-659.
• [2]Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV: Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 2003, 41:3655-3660.
• [3]Chen HC, Lin WL, Lin CC, Hsieh WH, Hsieh CH, Wu MH, Wu JY, Le CC: Outcome of inadequate empirical antibiotic therapy in emergency department patients with community-onset bloodstream infections. J Antimicrob Chemother 2013, 68:947-953.
• [4]Retamar P, Portillo MM, Lopez-Prieto MD, Rodríguez-López F, De Cueto M, García MV, Gómez MJ, Del Arco A, Muñoz A, Sánchez-Porto A, Torres-Tortosa M, Martín-Aspas A, Arroyo A, García-Figueras C, Acosta F, Corzo JE, León-Ruiz L, Escobar-Lara T, Rodríguez-Baño J: Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012, 56:472-478.
• [5]Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW: Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
• [6]Morata L, Cobos-Trigueros N, Martínez JA, Martínez JA, Soriano A, Almela M, Marco F, Sterzik H, Núňez R, Hernández C, Mensa J: Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012, 56:4833-4837.
• [7]Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
• [8]Hoffken G, Niederman MS: Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002, 122:2183-2196.
• [9]Niederman MS: The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2006, 27:45-50.
• [10]Niederman MS, Soulountsi V: De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? Clin Chest Med 2011, 32:517-534.
• [11]Souli M, Galani I, Giamarellou H: Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13:47.
• [12]Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opsal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2001, 2003(31):1250-1256.
• [13]Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med 1997, 15:148-151.
• [14]Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas V, Kotanidou A, Roussos C, Giamarellou H: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008, 46:1157-1164.
• [15]Calandra T, Cohen J: The International Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med 2005, 33:1639-1648.
• [16]Valles J, Palomar M, Alvárez-Lerma F, Rello J, Blanco A, Garnacho-Montero J, Martin-Loeches I: Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med 2013, 41:76-83.
• [17]Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
• [18]Rodríguez-Baño J, López-Prieto MD, Portillo MM, Retamar P, Natera C, Nuño E, Herrero M, Del Arco A, Muñoz A, Téllez F, Torres-Tortosa M, Martín-Aspas A, Arroyo A, Ruiz A, Moya R, Corzo JE, León L, Pérez-López JA: Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin Microbiol Infect 2010, 16:1408-1413.
• [19]Ammerlaan HS, Harbarth S, Buiting AG, Crook DW, Fitzpatrick F, Hanberger H, Herwalt LS, van Keulen PH, Kluytmans JA, Kola A, Kuckenbecker RS, Lingaas E, Meessen N, Morris-Downes MM, Pottinger JM, Rohner P, dos Santos RP, Seifert H, Wisplinghoff H, Ziesing S, Walker AS, Bonten MJ: Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 2013, 56:798-805.
• [20]Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H: An outbreak of infection due to beta-lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010, 50:364-373.
• [21]Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
• [22]Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Márquez-Vácaro JA: De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014, 40:32-40.
• [23]Brun-Buisson C, Meshaka P, Pinton P, Vallet B: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004, 30:580-588.